Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Markus Jackson

Interventional Pain Medicine Modesto, CA Medical Doctor

NPI 1548656937 CMS profile 2863267

4016 Dale Rd, Modesto, CA 95356

Open in the dashboard

General payments

$20,284

226 records reported · program years 2019–2025

Research payments

$16

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Markus Jackson of Modesto, CA is reported in the CMS Open Payments database as having received $20,284 across 226 general payments and $16 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $909 25
2024 General $3,993 45
2023 General $5,021 42
2022 General $6,737 56
2021 General $789 14
2021 Research $16 1
2020 General $764 18
2019 General $2,071 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Markus Jackson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Markus Jackson were reported at $909. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Markus Jackson Interventional Pain Medicine median Middle half National median
2019 $2,071 $684 $216–$2,079 $163
2020 $764 $382 $122–$1,109 $114
2021 $789 $552 $167–$1,554 $132
2022 $6,737 $605 $187–$1,924 $149
2023 $5,021 $671 $195–$1,915 $160
2024 $3,993 $684 $206–$1,837 $164
2025 $909 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $2,859 11 payments
  2. Boston Scientific Corporation $2,581 61 payments
  3. Painteq LLC $2,571 32 payments
  4. Medtronic, Inc. $2,363 25 payments
  5. SI-BONE, Inc. $1,915 8 payments
  6. Spinal Simplicity, LLC $1,165 7 payments
  7. Vertos Medical, Inc. $1,159 5 payments
  8. Nevro Corp. $1,099 15 payments
  9. Aurora Spine, Inc. $1,069 1 payment
  10. SPR Therapeutics, Inc $795 10 payments
  11. Other $2,708 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,048 39 payments
  2. Food and Beverage $9,833 186 payments
  3. Consulting Fee $402 1 payment
Products named General payments · program years 2019–2025
  1. PAINTEQ $2,571 32 payments
  2. Evoke SCS $1,745 6 payments
  3. VANTA ADAPTIVESTIM $1,348 14 payments
  4. IFUSE IMPLANT SYSTEM $1,202 4 payments
  5. HA MINUTEMAN G3-R $1,165 7 payments
  6. mild Device Kit $1,159 5 payments
  7. Evoke $1,114 5 payments
  8. ZIP $1,069 1 payment
  9. SPECTRA WAVEWRITER $957 4 payments
  10. SPRINT PNS System $765 9 payments
  11. Other $7,540 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

433

Median for Pain Management: 951

Drug cost

$21,490

Median for Pain Management: $26,034

Branded share of claims

9.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 27 $10,864
Gabapentin Generic 57 $2,360
Tizanidine Hcl Generic 17 $2,308
Desipramine Hcl Generic 25 $2,276
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 40 $1,108
Fentanyl Generic 12 $811
Oxycodone Hcl Generic 92 $598
Cephalexin Generic 89 $516
Methocarbamol Generic 22 $284
Baclofen Generic 14 $231

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$91,750

Medicare's payments for the services billed

Medicare patients

268

Average age 71

Services billed

1,099

168 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 30%
Ischemic heart disease 26%
Chronic kidney disease 24%
Atrial fibrillation 18%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record